Patents by Inventor Tong-Shuang Li

Tong-Shuang Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9701693
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: July 11, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold G. Selnick
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9409924
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: August 9, 2016
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Tong-Shuang Li, Ernest McEachern, David Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold Selnick
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9199949
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: December 1, 2015
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Tong-Shuang Li, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Harold G. Selnick
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9120781
    Abstract: The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: September 1, 2015
    Assignees: Simon Fraser University, Merck Sharp & Dohme Corp., Alectos Therapeutics Inc.
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Kun Liu, Harold G. Selnick
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 8962664
    Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: February 24, 2015
    Assignee: Simon Fraser University
    Inventors: David Vocadlo, Ernest McEachern, Keith Stubbs, Tong-Shuang Li, Garrett Whitworth, Julia Heinonen, Matthew Macauley
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20150045346
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: June 27, 2012
    Publication date: February 12, 2015
    Applicants: MERCK SHARP & DOHME CORP., ALECTOS THERAPEUTICS INC.
    Inventors: Tong-Shuang Li, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Harold G. Selnick
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140296205
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: June 27, 2012
    Publication date: October 2, 2014
    Applicants: MERCK SHARP & DOHME CORP., ALECTOS THERAPEUTICS INC.
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold G. Selnick
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140275022
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: June 27, 2012
    Publication date: September 18, 2014
    Applicants: MERCK SHARP & DOHME CORP., ALECTOS THERAPEUTICS INC.
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold G. Selnick
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20130131044
    Abstract: The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 23, 2013
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 8334310
    Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: December 18, 2012
    Assignee: Simon Fraser University
    Inventors: David Vocadlo, Ernest McEachern, Keith Stubbs, Tong-Shuang Li, Garrett Whitworth, Julia Heinonen, Matthew Macauley
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20120316207
    Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: August 22, 2012
    Publication date: December 13, 2012
    Applicant: Simon Fraser University
    Inventors: David Vocadlo, Ernest McEachern, Keith Stubbs, Tong-Shuang Li, Garrett Whitworth, Julia Heinonen, Matthew Macauley
  • CHEMOKINE RECEPTOR BINDING COMPOUNDS
    Publication number: 20100298366
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: August 5, 2010
    Publication date: November 25, 2010
    Applicant: Genzyme Corporation
    Inventors: Yuanxi ZHOU, Elyse Bourque, Yongbao Zhu, Jonathan Langille, Markus Metz, Wen Yang, Ernest J. Mceachern, Curtis Harwig, Ian R. Baird, Tong-Shuang Li, Renato T. Skerlj
  • Chemokine receptor binding compounds
    Patent number: 7790747
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: September 7, 2010
    Assignee: Genzyme Corporation
    Inventors: Yuanxi Zhou, Elyse Bourque, Yongbao Zhu, Jonathan Langille, Markus Metz, Wen Yang, Ernest J. McEachern, Curtis Harwig, Ian R. Baird, Tong-Shuang Li, Renato T. Skerlj
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20100016386
    Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc
    Type: Application
    Filed: August 31, 2007
    Publication date: January 21, 2010
    Inventors: David Vocadlo, Ernest McFachern, Keith Stubbs, Tong-Shuang Li, Garrett Whitworth, Julia Heinonen, Matthew Macauley
  • Chemokine receptor binding compounds
    Publication number: 20090099205
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: June 14, 2006
    Publication date: April 16, 2009
    Inventors: Yuanxi Zhou, Elyse Bourque, Yongbao Zhu, Jonathan Langille, Markus Metz, Wen Yang, Ernest J. McEachern, Curtis Harwig, Ian R. Baird, Tong-Shuang Li, Renato T. Skerlj
  • Chemokine receptor binding compounds
    Patent number: 7498346
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: March 3, 2009
    Assignee: Genzyme Corporation
    Inventors: Yuanxi Zhou, Gary J. Bridger, Renato T. Skerlj, David Bogucki, Wen Yang, Elyse Bourque, Jonathan Langille, Tong-Shuang Li, Markus Metz
  • Chemokine receptor binding compounds
    Patent number: 7491735
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: February 17, 2009
    Assignee: Genzyme Corporation
    Inventors: Yuanxi Zhou, Gary J. Bridger, Renato T. Skerlj, David Bogucki, Wen Yang, Elyse Bourque, Jonathan Langille, Tong-Shuang Li, Markus Metz, Maria R. Di Fluri, Siqiao Nan
  • Chemokine receptor binding compounds
    Publication number: 20070066624
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: August 16, 2006
    Publication date: March 22, 2007
    Applicant: AnorMED, Inc.
    Inventors: Yuanxi Zhou, Elyse Bourque, Yongbao Zhu, Ernest McEachern, Curtis Harwig, Renato Skerlj, Gary Bridger, Tong-Shuang Li, Markus Metz
  • Chemokine receptor binding compounds
    Publication number: 20050277670
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: December 13, 2004
    Publication date: December 15, 2005
    Inventors: Yuanxi Zhou, Gary Bridger, Renato Skerlj, David Bogucki, Wen Yang, Elyse Bourque, Jonathan Langille, Tong-Shuang Li, Markus Metz, Maria Di Fluri, Siqiao Nan
  • Chemokine receptor binding compounds
    Publication number: 20050277668
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: June 14, 2005
    Publication date: December 15, 2005
    Inventors: Yuanxi Zhou, Gary Bridger, Renato Skerlj, David Bogucki, Wen Yang, Elyse Bourque, Jonathan Langille, Tong-Shuang Li, Markus Metz